April 28, 2020 08:34 AM EDTUpdated 11:41 AM

Vertex's cystic fibrosis drugs work, but they're too expensive, ICER finds

Natalie Grover

Reporter

Earlier this month, Reshma Kewalramani took over the reins as Vertex Pharmaceuticals’ CEO — she will now be tasked with grappling with criticism from cost …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vertex's cystic fibrosis drugs work, but they're too expensive, ICER finds

Natalie Grover

Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Ver­tex's cys­tic fi­bro­sis drugs work, but they're too ex­pen­sive, ICER finds

Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Vertex's cystic fibrosis drugs work, but they're too expensive, ICER finds